Clinical Trial Update: Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) [Phase 3]

View source ↗

Summary

Phase 3 trial results for RBX2660, a microbiota restoration therapy, in recurrent Clostridioides difficile infection have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• RBX2660 (RBX2660)

Snippet

Sponsor: Rebiotix Inc. | Conditions: Clostridium Difficile Infection, Infection | Phase 3 | Status: COMPLETED | Results posted: 2024-08-07